Chloe Wang is an associate in Mayer Brown's New York office and a member of the Corporate & Securities practice.  Chloe's practice focuses on insurance and reinsurance, mergers and acquisitions, and other corporate transactions across a variety of industries, including energy and infrastructure, health science, and food and beverage. Chloe advises clients in US and cross-border asset and stock acquisitions and divestitures, joint ventures, strategic alliances, commercial transactions, reinsurance transactions and general corporate matters.  


Energy and Infrastructure

  • Represented Brookfield Infrastructure in the $4.1 billion sale of its wholly-owned North American district energy business, Enwave.


  • Advised reinsurers or cedents in various closed block or flow reinsurance transactions in the life and annuity sector.
  • Represented The Hartford Financial Services Group, Inc. (NYSE:HIG) on its agreement to sell its Navigators continental European insurance business to Premia Holdings Ltd.
  • Advised Armour Group on its acquisition of QBE's discontinued US program insurance business through loss portfolio transfer and administration arrangement.

Private Equity

  • Represented The Jordan Company in the sale of its portfolio company DuBois Chemicals to Altas Partners.
  • Represented The Jordan Company in the sale of its portfolio company Drew Marine

Life Science

  • Represented Nestlé Health Science in its acquisition of IM HealthScience with its brands of IBgard®, FDgard®, Fiber Choice® and REMfresh®
  • Represented Adapt Pharma Limited, makers of opioid overdose treatment NARCAN®, in its sale to Emergent BioSolutions, Inc.

Capital Markets

  • Advised agents in exempt medium term notes offerings.
  • Represented GW Pharmaceuticals in $345.2 million Nasdaq offering.
  • Advised client in Exchange Act compliance matters, including Section 16, 10Q, 10K and Schedule 13 filings.


Harvard Law School, JD

University of International Business and Economics, BA


  • New York